Investor Information
Cancer is personal. We’ve all felt its devastating impact - the pain, the uncertainty, and the helplessness - whether on ourselves or those we love. At Australis, we are committed to changing this narrative. But we can’t do it alone. We are looking for additional good-hearted “Accredited Investors” (or similar in non-US and Australian countries) which would allow us to pursue more cancers, with additional childhood cancers as the top priority.
For more information, please contact: trobinson@australispharma.com
About AUS_001
AUS_001 is a compound discovered in honeybee propolis on Kangaroo Island, South Australia. In vitro, it eliminated 24 cancers, and in vivo, it demonstrated strong efficacy against seven types of cancers (to date) with minimal side effects.
Taken orally, AUS_001 could potentially offer patients the convenience of taking their medication at home. The pre-clinical data also demonstrated a wide therapeutic index. Beyond cancer, AUS_001 also shows promise for treating inflammatory and neurodegenerative diseases
About the founder
Todd Robinson is the founder of Australis and the owner of the land where AUS_001 was discovered. He led the company’s operations until 2024, when he handed the reins over to current CEO Michele Korfin. While no longer involved in the day-to-day running of the business, Todd continues to provide strong strategic guidance, helping to shape the long-term direction of Australis.
Who is Australis?
Australis is a global biopharmaceutical company deeply driven to bring new therapies to cancer patients in need. Our in-house research is centered around our laboratory in Simi Valley, California, by a team of dedicated PhD scientists.
Our third-party research is performed and reviewed by esteemed professionals worldwide.
Michele Korfin
CEO (RPh, MBA)
Caroline Carr
CFO (CPA)
Marina Koutsioumpa
VP of Cancer Biology (PhD)
Herman Lelie
VP of Research and Development (PhD)
Be part of a life-changing solution for cancer patients
Make a meaningful impact
Learn more about a treatment that could potentially save millions of lives and bring real change to cancer care. If you would like to honor the memory of loved ones, please contact info@australispharma.com
Transform cancer treatment
AUS_001 is a groundbreaking therapy with pre-clinical efficacy across 24 cancer types, including challenging cancers like pancreatic cancer and glioma.
Innovative and safe
In pre-clinical models, AUS_001 demonstrated both an encouraging efficacy and safety profile.
Corporate presentations
We encourage you to download our corporate presentation for detailed pre-clinical data, research, results, and more.
Frequently asked questions
We have successfully raised $30M over the last 10+ years and, as of 2025, have no third-party debt on the balance sheet. We have enough cash on hand to proceed through at least Phase 1.
Please email us directly for more information (subject to an NDA).
In 2025, we received the exciting news that we’ve received for AUS_001, both Orphan Drug Designation for malignant gliomas and Rare Pediatric Disease Designation for pediatric-type diffuse high-grade gliomas!
Our objective is to raise $10M-$50M in capital to launch additional human trials beyond Phase 1 in more cancers, particularly childhood cancers. For more information, please visit our Investors page.
We have had very strong academic collaborations as noted in our published posters. Please contact us directly for a comprehensive list.
Invest in the future of cancer care
Are you passionate about improving cancer treatment and ready to help bring AUS_001 to patients who need it?